We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

27 hedge funds and large institutions have $20.3M invested in Protara Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

8% more funds holding

Funds holding: 25 → 27 (+2)

0.2% more ownership

Funds ownership: 1.27% → 1.47% (+0.2%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

7% less capital invested

Capital invested by funds: $21.9M → $20.3M (-$1.6M)

Holders
27
Holders Change
+2
Holders Change %
+8%
% of All Funds
0.62%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
4
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NLVP
New Leaf Venture Partners
New York
+$3.46M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$152K
3
Renaissance Technologies
Renaissance Technologies
New York
+$69K
4
BFM
Boothbay Fund Management
New York
+$60.5K
5
VF
Virtu Financial
New York
+$32.6K

Top Sellers

1
PA
Perceptive Advisors
New York
-$216K
2
DS
DRW Securities
Illinois
-$113K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$45K
4
PAM
Panagora Asset Management
Massachusetts
-$10.5K
5
UBS Group
UBS Group
Switzerland
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1K +$1.01K +11 New
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
– -$45K -464 Closed
UBS Group
28
UBS Group
Switzerland
– -$5K -55 Closed
BA
29
Ballew Advisors
Mississippi
– +$92 +1 New
1
2

TARA Hedge Fund Activity: Q3 2018 in Review

27 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2018, worth a combined $20.3M — down 7.3% from $21.9M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TARA positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $3.46M. The largest seller was Perceptive Advisors, cutting an estimated $216K.

  • 27 institutional investors held Protara Therapeutics (TARA) as of Q3 2018, up from 25 in Q2 2018.
  • Funds reported $20.3M of Protara Therapeutics stock for Q3 2018, down 7.3% quarter-over-quarter.
  • 4 funds opened new Protara Therapeutics positions in Q3 2018 and 2 closed out, a net change of +2 holders.
  • The largest Protara Therapeutics buyer in Q3 2018 was New Leaf Venture Partners, an estimated $3.46M added.
  • The largest Protara Therapeutics seller in Q3 2018 was Perceptive Advisors, an estimated $216K sold.

Based on aggregated 13F filings for Q3 2018.